Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.52 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14523845 | 1.00 | MAOB (0.52) | MAOBCAPN1PARP1MAOAXDH | |
| SCHEMBL14523859 | 0.87 | PTPN1 (0.47) | MAOBCAPN1PARP1MAOAMEN1 | |
| SCHEMBL30834905 | 0.82 | NFKB1 (0.53) | MAOBCAPN1PARP1MAOAMEN1 | |
| SCHEMBL27567793 | 0.79 | CTSV (0.40) | MAPTLMNATDP1ALDH1A1CYP3A4 | |
| Xanthohumol B SCHEMBL12961703 | 0.79 | NFKB1 (0.56) | MAOBCAPN1PARP1MAOAMAPT | |
| Xanthohumol B SCHEMBL29934961 | 0.79 | NFKB1 (0.56) | MAOBCAPN1PARP1MAOAMAPT | |
| SCHEMBL4485920 | 0.78 | MAOB (0.52) | MAOBCAPN1PARP1MAOAXDH | |
| SCHEMBL4485916 | 0.78 | MAOB (0.52) | MAOBCAPN1PARP1MAOAXDH | |
| SCHEMBL25256060 | 0.76 | MAPT (0.53) | MAOBMAOAMEN1KMT2AMAPT | |
| SCHEMBL16698051 | 0.74 | HDAC1 (0.68) | MAOBCAPN1PARP1MAOAXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078386-B2 | Enhancing agent for nerve growth factor production comprising a compound having a coumarin backbone or a compound having a 2-dimethyl chroman backbone | TAKARA BIO, INC. (JP) | 2006-07-18 | — | — | US | claimed |
| US-20040122082-A1 | Remedies | TAKARA BIO INC. (JP) | 2004-06-24 | — | — | US | claimed |
| CN-1501922-A | Remedies | �����﹤����ʽ���� | 2004-06-02 | — | — | CN | claimed |
| EP-1386919-A1 | REMEDIES | TAKARA BIO INC. (JP) | 2004-02-04 | — | — | EP | claimed |
| CN-100516059-C | Remedies | TAKARA BIO INC (JP) | 2009-07-22 | — | — | CN | disclosed |
| US-20060199774-A1 | Intensify nerve growth factor; using chroman compound | OHNOGI HIROMU | 2006-09-07 | — | — | US | disclosed |
| US-7078386-B2 | Enhancing agent for nerve growth factor production comprising a compound having a coumarin backbone or a compound having a 2-dimethyl chroman backbone | TAKARA BIO, INC. (JP) | 2006-07-18 | — | — | US | disclosed |
| US-20040219238-A1 | Prophylactic agent for enhancement of nerve growth factor production for treatment or prevention comprising an aqueous mushroom extract (xanthohumol or salts) ; neurodegenerative diseases, Alzheimer*s disease, and nervoxanthohumol andus system disorders; foods, beverages, feeds; | TAKARA BIO INC. (JP) | 2004-11-04 | — | — | US | disclosed |
| US-20040122082-A1 | Remedies | TAKARA BIO INC. (JP) | 2004-06-24 | — | — | US | disclosed |
| CN-1501922-A | Remedies | �����﹤����ʽ���� | 2004-06-02 | — | — | CN | disclosed |
| EP-1415657-A1 | REMEDIES | TAKARA BIO INC. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1386919-A1 | REMEDIES | TAKARA BIO INC. (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199774-A1 | Intensify nerve growth factor; using chroman compound | NGF, BDNF, FGF1 | MAOB 1534/4885CAPN1 1627/4885PARP1 4106/4885 |
| US-20040122082-A1 | Remedies | NGF, BDNF, NGFR | MAOB 48/4885CAPN1 2131/4885PARP1 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.